Listing 1 - 10 of 608 | << page >> |
Sort by
|
Choose an application
Soft tissue and bone sarcomas disproportionately affect children, adolescents, and young adults. Although considered a rare disease, sarcomas continue to have a devastating effect on these patients and their loved ones, and their impact on our society far exceed their relatively low prevalence. Because of its rarity and heterogeneity, clinical decision making on management of sarcomas are often individualized and without a consensus treatment strategy. Furthermore, research to improve clinical outcomes are particularly challenging as sizeable studies are hard to produce. By improving our knowledge about the molecular biology of sarcomas, we hope to identify new treatment strategies and targets for further drug development.
Choose an application
This book reviews the brilliant progress made in the past three decades in clinical outcomes for osteosarcoma patients treated with a multidisciplinary approach, including limb-salvage surgery combined with neoadjuvant multidrug chemotherapy and aggressive management of pulmonary metastasis. Osteosarcoma was a miserable disease for adolescents and young adults until the early 1970s, with a survival rate that was less than 10-15% even after amputation for affected limbs because of the progression of pulmonary metastasis. With the development of neoadjuvant chemotherapy for osteosarcoma, including high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide during the late 1970s and the 1980s, however, the prognosis has dramatically improved. Limb-salvage surgery for patients with extremity osteosarcoma is now a gold-standard surgical procedure for more than 90% of patients with localized disease. Additionally, aggressive pulmonary metastasectomy for patients with lung metastasis from osteosarcoma has contributed to improvement of their survival. More recently, carbon-ion radiotherapy has also been introduced for patients with unresectable osteosarcoma of the trunk, as in the spine and pelvis. In this volume the author provides valuable descriptions of an important new treatment modality for a multidisciplinary approach for osteosarcoma patients.
Choose an application
This book reviews the brilliant progress made in the past three decades in clinical outcomes for osteosarcoma patients treated with a multidisciplinary approach, including limb-salvage surgery combined with neoadjuvant multidrug chemotherapy and aggressive management of pulmonary metastasis. Osteosarcoma was a miserable disease for adolescents and young adults until the early 1970s, with a survival rate that was less than 10-15% even after amputation for affected limbs because of the progression of pulmonary metastasis. With the development of neoadjuvant chemotherapy for osteosarcoma, including high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide during the late 1970s and the 1980s, however, the prognosis has dramatically improved. Limb-salvage surgery for patients with extremity osteosarcoma is now a gold-standard surgical procedure for more than 90% of patients with localized disease. Additionally, aggressive pulmonary metastasectomy for patients with lung metastasis from osteosarcoma has contributed to improvement of their survival. More recently, carbon-ion radiotherapy has also been introduced for patients with unresectable osteosarcoma of the trunk, as in the spine and pelvis. In this volume the author provides valuable descriptions of an important new treatment modality for a multidisciplinary approach for osteosarcoma patients.
Choose an application
Soft tissue and bone sarcomas disproportionately affect children, adolescents, and young adults. Although considered a rare disease, sarcomas continue to have a devastating effect on these patients and their loved ones, and their impact on our society far exceed their relatively low prevalence. Because of its rarity and heterogeneity, clinical decision making on management of sarcomas are often individualized and without a consensus treatment strategy. Furthermore, research to improve clinical outcomes are particularly challenging as sizeable studies are hard to produce. By improving our knowledge about the molecular biology of sarcomas, we hope to identify new treatment strategies and targets for further drug development.
Choose an application
This book reviews the brilliant progress made in the past three decades in clinical outcomes for osteosarcoma patients treated with a multidisciplinary approach, including limb-salvage surgery combined with neoadjuvant multidrug chemotherapy and aggressive management of pulmonary metastasis. Osteosarcoma was a miserable disease for adolescents and young adults until the early 1970s, with a survival rate that was less than 10-15% even after amputation for affected limbs because of the progression of pulmonary metastasis. With the development of neoadjuvant chemotherapy for osteosarcoma, including high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide during the late 1970s and the 1980s, however, the prognosis has dramatically improved. Limb-salvage surgery for patients with extremity osteosarcoma is now a gold-standard surgical procedure for more than 90% of patients with localized disease. Additionally, aggressive pulmonary metastasectomy for patients with lung metastasis from osteosarcoma has contributed to improvement of their survival. More recently, carbon-ion radiotherapy has also been introduced for patients with unresectable osteosarcoma of the trunk, as in the spine and pelvis. In this volume the author provides valuable descriptions of an important new treatment modality for a multidisciplinary approach for osteosarcoma patients.
Choose an application
Choose an application
Soft tissue and bone sarcomas disproportionately affect children, adolescents, and young adults. Although considered a rare disease, sarcomas continue to have a devastating effect on these patients and their loved ones, and their impact on our society far exceed their relatively low prevalence. Because of its rarity and heterogeneity, clinical decision making on management of sarcomas are often individualized and without a consensus treatment strategy. Furthermore, research to improve clinical outcomes are particularly challenging as sizeable studies are hard to produce. By improving our knowledge about the molecular biology of sarcomas, we hope to identify new treatment strategies and targets for further drug development.
Choose an application
Connective tissues --- Connective tissues --- Diseases. --- Diseases.
Choose an application
Connective tissues --- Diseases. --- Rheumatology
Choose an application
Connective tissue diseases (CTDs) comprise a number of systemic autoimmune disorders and related conditions characterized by rheumatic manifestations, production of myriad autoantibodies, and varied immune-mediated organ injury. To achieve the best outcomes for patients, accurate evaluation has become critical, and thus advanced diagnostic and assessment modalities have been developed that have had a revolutionary impact in precise characterization of the disease conditions in CTDs. This book provides an in-depth look at the current state of CTDs, while also presenting an overview that is easily understandable to newcomers to the field. Chapters cover such conditions as rheumatoid arthritis, lupus, systemic sclerosis spectrum diseases, and spondyloarthritis, as well as the importance of physical activity and exercise training in the clinical course of CTDs.
Listing 1 - 10 of 608 | << page >> |
Sort by
|